The Tray Comes Back Half-Full: Hospitalized Cancer Patients Miss Up to 1,000 Calories a Day

The scan results are on the screen, and the news is not good. The pancreatic cancer has grown through two rounds of chemotherapy. The oncologist starts talking about what is left — and the honest truth is that, at this point, the list is short.

Pancreatic cancer is one of the hardest cancers to treat, and once standard chemotherapy stops working, later treatments usually shrink tumors in only a small share of patients. Most people in this situation are told to hope for stability, not shrinkage.

That is why a set of early trial results released on October 23, 2026, at the European Society for Medical Oncology (ESMO) Congress in Madrid turned so many heads.

In a Phase 1/2 trial of two oral, once-daily pills — vopimetostat and daraxonrasib — taken together, tumors shrank in 82% of patients with a specific genetic type of advanced pancreatic cancer. These were not newly diagnosed patients. Most had already been through two earlier treatments. And the regimen contains no chemotherapy at all.

This post explains what was actually found — the hopeful parts and the honest limits — in plain language: who these drugs are for, how they work, what the side effects looked like, and what happens next.

One caution up front, because it matters: this was a small, early trial of an investigational treatment. It is a reason for real hope and for a much bigger trial. It is not a new standard of care, and it is not FDA-approved. Holding both of those ideas at once is the right way to read everything below.

What Is Pancreatic Cancer — and Why Is It So Hard to Treat?

Pancreatic cancer starts in the pancreas, the organ tucked behind the stomach that makes digestive enzymes and insulin. The most common type is pancreatic ductal adenocarcinoma, shortened to PDAC.

Several things make it one of the most difficult cancers doctors face:

• It hides early. The pancreas sits deep in the body, and early pancreatic cancer rarely causes clear symptoms. Most people are diagnosed after it has already spread.
• It grows fast and spreads early. By the time it is found, surgery — the only chance at a cure — is often no longer possible.
• It resists treatment. Pancreatic tumors are wrapped in dense tissue that drugs struggle to reach, and the cancer cells themselves are unusually good at surviving.
• Chemotherapy options wear out. Standard chemotherapy can help, but in the second and third rounds of treatment ("lines" of therapy), tumors shrink in only a small minority of patients — and the benefit usually lasts months, not years.

That background is what makes an 82% response rate worth a second look. In later-line pancreatic cancer, even a 20–30% response rate would be notable. A number this high, in patients this heavily pretreated, is the kind of signal researchers are trained to chase — carefully.

The Myth: "If It Isn't Chemotherapy, It Isn't Real Treatment for Pancreatic Cancer"

Because chemotherapy has carried almost the entire load in pancreatic cancer for decades, it is easy to assume nothing else can work. Targeted drugs — pills designed to attack specific genetic flaws in a tumor — have transformed lung cancer and several other cancers, but pancreatic cancer has mostly been left out of that revolution.

Here is the misconception this trial pushes against: that pancreatic cancer is one disease that only answers to one kind of treatment.

In reality, pancreatic cancers differ from each other at the genetic level. The patients in this trial were chosen because their tumors carried two specific features:

• A deleted gene called MTAP, and
• A mutation in a gene family called RAS — the same family that includes KRAS, mutated in the great majority of pancreatic cancers.

Two patients can both have "pancreatic cancer" and have tumors running on very different machinery. This trial matched two drugs to two specific parts of that machinery. Think of it less like carpet-bombing and more like cutting the two wires the tumor depends on most.

Chemotherapy treats pancreatic cancer as one disease. This trial treated it as a genetic disease — and picked patients whose tumors had the exact flaws the drugs were built to exploit.

How Do Vopimetostat and Daraxonrasib Work?

The first wire: MTAP deletion and PRMT5

MTAP is a gene that normally helps cells recycle a chemical building block. In a large share of pancreatic tumors, MTAP is deleted — missing entirely.

That loss creates a weakness. Without MTAP, a leftover chemical (called MTA) builds up inside the cancer cell and partially jams an enzyme called PRMT5, which the cell needs to copy itself and survive. The cell is still running, but its PRMT5 engine is already sputtering.

Vopimetostat is a pill that blocks PRMT5 further. In a normal cell, with healthy MTAP, that extra block is tolerable. In an MTAP-deleted cancer cell, it can be fatal — the engine stalls completely.

Doctors call this "synthetic lethality," but the everyday picture is simpler: the tumor has already sawn halfway through one of its own support beams. Vopimetostat pushes on exactly that beam.

The second wire: RAS, the growth switch

RAS genes are growth switches. When a RAS gene mutates — as KRAS does in most pancreatic cancers — the switch gets stuck in the "on" position, telling the cell to grow and divide nonstop.

For decades, RAS was considered "undruggable." Daraxonrasib belongs to a newer class called RAS(ON) inhibitors, designed to block the switch while it is in its active, "on" state. (Daraxonrasib itself was approved earlier in 2026 for some RAS-mutant pancreatic cancers, which is part of why this combination could move quickly.)

Why two drugs together?

Each drug attacks a different dependency. Vopimetostat exploits the MTAP deletion; daraxonrasib shuts down the RAS growth signal. The bet behind the trial is that a tumor cornered on two fronts is less likely to escape on either one — and the early response numbers suggest the bet is worth testing at full scale.

Both drugs are oral and taken once a day. No infusion chair. No IV line. That detail matters more than it might sound, and we will come back to it.

Why This News Matters in Real Life

• Later-line patients are the ones with the fewest options. More than half of the patients in this trial were on their third line of therapy — the point where oncologists often run out of standard treatments to offer. Results in this group matter precisely because the cupboard is usually bare.
• Shrinkage is different from stability. "Disease control" can mean a tumor simply stopped growing. An 82% response rate means tumors measurably shrank in 18 of 22 patients — the outcome patients actually hope for.
• No chemotherapy means a different daily life. Both drugs are once-daily pills taken at home. There is no five-hour infusion day, no port, no post-chemo crash days built into the schedule — the kind of "time toxicity" burden we described in our post on what chemotherapy's burden really costs patients.
• It is biomarker-driven hope, not blanket hope. The catch is real: this applies to patients whose tumors are MTAP-deleted and RAS-mutant. Genetic testing of the tumor is the gatekeeper, which makes testing itself part of the story.

What Did the New Trial Find?

The study is an ongoing Phase 1/2 trial (NCT06922591) of vopimetostat combined with a RAS(ON) inhibitor, run by Tango Therapeutics. The updated results were released October 23, 2026, and presented at ESMO 2026 in Madrid.

The basics:

• Who: patients with metastatic pancreatic cancer (PDAC) whose tumors were MTAP-deleted and RAS-mutant, and who had already received prior treatment.
• The main group: 22 patients could be evaluated for response (they had started treatment at least 14 weeks before the data cutoff). 13 of the 22 were on their third line of therapy.
• The treatment: vopimetostat (200 mg once daily at the main dose level) plus daraxonrasib (100 mg once daily) — both pills, no chemotherapy.
• Data cutoff: August 20, 2026, with a median follow-up of 7.1 months — long enough to see whether responses were real, too short to know how long they will last.
• The honest fine print: this is a single-arm study — every patient got the drugs, and there is no comparison group. Phase 1/2 trials are designed mainly to find the right dose and look for early signals, not to prove a treatment works.

Finding 1: Tumors shrank in 82% of patients

The objective response rate was 82% — 18 of 22 patients had their tumors shrink.

At the data cutoff, 11 of those responses were confirmed on follow-up scans and 7 were still awaiting confirmation; the company reports all 7 were confirmed after the cutoff.

Translate that into a room of 22 people who had already been through two rounds of chemotherapy: 18 of them saw their tumors get smaller on a pill regimen. In later-line pancreatic cancer, that is a number researchers simply do not see from chemotherapy.

Tango's CEO said the results "surpass any published PDAC datasets, even in front-line settings." That is a company claim, and it should be read as one — but it explains why this small trial drew outsized attention at the conference.

Finding 2: The benefit looks durable — so far

Response only matters if it lasts. Here, the early durability signals are strong:

• Median progression-free survival had not yet been reached — at the time of the report, the typical patient had not yet seen their cancer grow again.
• 88% of patients were progression-free at 9 months.
• Disease control was 100% — every evaluable patient's cancer at least stopped growing.

One of the trial's investigators, Dr. Alexander Spira, pointed to exactly this: most patients remained progression-free at nine months "despite being heavily pretreated," on an oral, chemotherapy-free regimen.

A response that vanishes in six weeks is a headline. A response still holding at nine months, in third-line pancreatic cancer, is a signal worth a Phase 3 trial.

Finding 3: The main dose was tolerable — the higher dose was not

Finding the right dose is the whole point of a Phase 1/2 trial, and this one delivered a clear answer.

At the main dose level (25 patients evaluated for safety):

• No dose-limiting toxicities and no one stopped treatment because of side effects.
• No Grade 4 or Grade 5 treatment-related side effects (the most serious categories).
• Grade 3 side effects occurred in 40% — real, but manageable, and one in five patients (20%) had their dose reduced.
• The most common side effects were all mild-to-moderate (Grade 1–2): mouth sores (stomatitis) in 48%, rash in 44%, and diarrhea in 28%.

At the higher dose level, the picture changed: 3 dose-limiting toxicities in 2 of just 4 patients. That dose was judged not well tolerated — which is why the planned Phase 3 will use the lower dose. More is not always better; this trial is a clean example of a study doing its dose-finding job.

Finding 4: A second pill pairing also worked

The same trial tested vopimetostat with a second RAS(ON) inhibitor, zoldonrasib, in patients whose tumors carried a specific RAS mutation called KRAS G12D.

• Response rate 54% (19 of 35 patients), including one complete response — a tumor that disappeared on scans.
• 61% progression-free at 9 months, and disease control of 97%.
• Safety looked similar: no treatment-related deaths, one Grade 4 event, Grade 3 side effects in 28%, and the most common issues were nausea (39%), vomiting (39%), taste changes (28%), and fatigue (26%) — all mild to moderate.

Two different pairings showing activity in the same genetic neighborhood strengthens the idea that the vopimetostat backbone — not just one lucky combination — is doing something real.

Finding 5: A make-or-break Phase 3 trial is planned for 2027

Tango has discussed the data with the FDA and plans a global, randomized Phase 3 trial starting in the first half of 2027:

• Who: patients newly starting treatment (front-line) whose tumors are MTAP-deleted.
• Design: vopimetostat + daraxonrasib versus standard chemotherapy — a head-to-head test, which is exactly what the Phase 1/2 data cannot provide.
• Main measures: response rate and progression-free survival, with overall survival as a key secondary measure.

The company also plans to talk with regulators about a possible approval path for patients in the second-line setting. Dr. Anna Berkenblit of the Pancreatic Cancer Action Network (PanCAN) summed up the advocacy view: the results "warrant rapid evaluation in a larger, randomized Phase 3 trial."

"Chemo-Free" Does Not Mean "Side-Effect-Free"

It would be easy to read this story as "pills good, chemo bad." Resist that. This regimen trades one set of burdens for another — lighter ones, on this early evidence, but real ones. And in pancreatic cancer, the side effects that matter most are often the ones that attack eating, drinking, and digestion, because the disease is already attacking them.

Look at the list through that lens:

• Mouth sores (48% at the main dose). Stomatitis makes eating and drinking hurt. Patients quietly eat less, drink less, and lose ground on hydration and nutrition — the two things a body fighting pancreatic cancer can least afford to lose.
• Diarrhea (28%). Every episode drains water and electrolytes — sodium, potassium, and magnesium. In a cancer where weight loss and malnutrition are already central threats, ongoing diarrhea is not a minor inconvenience; it is an accelerant.
• Nausea, vomiting, and taste changes (most visible in the zoldonrasib pairing: 39%, 39%, and 28%). Food that tastes wrong does not get eaten. Meals skipped become pounds lost, and pounds lost become muscle lost — the downward spiral we described in our post on cancer cachexia and early weight loss.
• The pancreas itself. Even before treatment, pancreatic tumors interfere with digestion and appetite. Treatment side effects land on a system that is already struggling.

That is the space HuMOLYTE was made for. HuMOLYTE is a medical food for use under medical supervision, designed to support hydration and electrolyte balance — including magnesium, which many standard drinks do not replace — and gut health during cancer treatment. It does not treat cancer, and no supportive-care product makes a targeted drug work better. What it supports is the daily foundation — fluids in, electrolytes replaced, gut supported — that helps a patient stay strong enough to stay on a treatment that is working.

Practical steps if you or a loved one is on a regimen like this:

• Treat mouth sores early. Report them at the first sign; soft foods, gentle oral care, and prompt treatment keep eating possible.
• Front-load fluids and electrolytes on days with diarrhea or poor intake, rather than trying to catch up once dehydration sets in.
• Track weight weekly. In pancreatic cancer, the scale is an early-warning system, not a vanity metric.
• Report taste changes and nausea before they shrink your meals — they are easier to counter early than after ten pounds are gone.

What Should Patients and Caregivers Watch For?

On any new cancer treatment, call the care team promptly if you notice:

• Mouth sores that make eating or drinking painful or impossible
• Diarrhea that lasts more than a day or two, or comes with dizziness or very low urine output (signs of dehydration)
• Nausea or vomiting that prevents keeping fluids down
• A rash that spreads, blisters, or comes with fever
• Weight loss of more than a few pounds between visits, or clothes suddenly fitting loosely
• New or worsening fatigue that interferes with basic daily activities
• Blood in the stool, black stools, severe belly pain, or yellowing of the skin or eyes
• Fever of 100.4°F (38°C) or higher, or any sign of infection

Questions to Ask Your Oncology Team

1. Has my tumor been tested for MTAP deletion and RAS or KRAS mutations? If not, can that testing be done on my existing biopsy?
2. If my tumor is MTAP-deleted, would I be eligible for the planned Phase 3 trial of vopimetostat plus daraxonrasib in 2027 — and where will it be open?
3. Are there any open trials of PRMT5 inhibitors or RAS inhibitors I could join now, rather than waiting for the Phase 3?
4. How do these early results compare with the standard options left for me at this line of therapy?
5. If I start a targeted-drug regimen, what side effects should I expect in the first month, and which ones should make me call you the same day?
6. Mouth sores and diarrhea were common in the trial. What is our plan to protect my eating, drinking, and electrolytes if they happen?
7. How will we track my weight and nutrition during treatment, and when would a dietitian or pancreatic enzyme replacement enter the picture?
8. What scans and blood work will show whether the treatment is working, and how soon?
9. If this approach is not an option for me, what is the most promising next step — another trial, a different regimen, or a focus on symptom control?
10. Who on the team handles supportive care — nutrition, hydration, pain, and fatigue — from day one, not just when problems appear?

Why This Trial Matters

Pancreatic cancer has a long history of promising headlines that did not survive bigger trials, and honest coverage has to say so. This one earns attention anyway, for three reasons.

First, the setting: heavily pretreated patients are where promising drugs usually go to look ordinary. An 82% response rate in mostly third-line patients is the opposite of ordinary.

Second, the mechanism: this is not a lucky one-off. It is a genetic strategy — find the tumor's deleted gene, exploit the weakness it creates, and block the growth switch at the same time. A second pairing in the same trial produced a 54% response rate, which supports the strategy rather than a single result.

Third, the life around the treatment: an oral, once-daily, chemotherapy-free regimen gives patients their days back. No infusion chair, no five-hour treatment days. For people measuring life in months, time at home is not a side benefit. It is close to the whole point.

The Bottom Line

• In a Phase 1/2 trial presented at ESMO 2026, the pill combination vopimetostat + daraxonrasib shrank tumors in 82% of patients (18 of 22) with MTAP-deleted, RAS-mutant metastatic pancreatic cancer — most of them on their third line of therapy.
• Responses look durable so far: 88% progression-free at 9 months, median progression-free survival not yet reached, and 100% disease control, at a median follow-up of 7.1 months.
• At the main dose, the regimen was manageable: mouth sores (48%), rash (44%), and diarrhea (28%), all mild to moderate; Grade 3 side effects in 40%; no Grade 4–5 treatment-related events and no one stopped for side effects. A higher dose was not tolerated and was dropped.
• A second pairing, with zoldonrasib, shrank tumors in 54% of patients with KRAS G12D tumors, including one complete response.
• The caveats are not fine print, they are the story's second half: 22 patients, no comparison group, an investigational drug, and results reported by the company developing it. Early pancreatic cancer signals have disappointed before.
• The test that matters comes next: a randomized Phase 3 trial against standard chemotherapy, planned to start in the first half of 2027.
• If you or a loved one has pancreatic cancer, the actionable step today is a question, not a drug: has this tumor been tested for MTAP deletion and RAS mutations? The answer increasingly decides which doors are open.

Hope in pancreatic cancer should always be audited. This result survives the audit as exactly what it is: an early, unusually strong signal that deserves its big trial — fast.

Frequently Asked Questions

What is vopimetostat?

Vopimetostat is an investigational, once-daily oral drug made by Tango Therapeutics. It blocks an enzyme called PRMT5. It is being studied mainly in cancers where a gene called MTAP is deleted, because those tumors are unusually dependent on PRMT5 to survive. It is not FDA-approved.

What is daraxonrasib?

Daraxonrasib is a RAS(ON) inhibitor developed by Revolution Medicines — a pill designed to block RAS proteins while they are switched "on." RAS mutations drive the growth of most pancreatic cancers. Daraxonrasib was approved earlier in 2026 for certain RAS-mutant pancreatic cancers, and in this trial it was combined with vopimetostat.

Who could this combination help?

So far, only patients whose pancreatic tumors carry both features the trial required: an MTAP deletion and a RAS mutation. That is a subset of pancreatic cancers, not all of them — which is why tumor genetic testing is the first step in finding out whether this research is relevant to a specific person.

What does an 82% response rate mean?

It means that among the 22 patients whose response could be measured, 18 had tumors that shrank by a meaningful amount on scans. It does not mean 82% of patients were cured, and it does not yet tell us whether patients live longer — that is what the planned Phase 3 trial is designed to test.

Is this treatment available now?

No. The combination is investigational and only available through clinical trials. The larger Phase 3 trial is planned to begin enrolling in the first half of 2027. Patients interested in earlier-stage trials of PRMT5 or RAS inhibitors can ask their oncologist or search ClinicalTrials.gov (this study is NCT06922591).

How is this different from chemotherapy?

Chemotherapy attacks cells that divide quickly — cancer cells, but also healthy cells in the gut, hair, and bone marrow. Vopimetostat and daraxonrasib are targeted drugs: each is designed to interfere with a specific genetic weakness or growth signal in the tumor. They are also both pills taken once a day at home, with no infusion visits. Targeted does not mean harmless, though — their side effects are different from chemotherapy's, not absent.

What were the most common side effects?

At the main dose of vopimetostat plus daraxonrasib, the most common were mouth sores (48%), rash (44%), and diarrhea (28%) — all mild to moderate. Grade 3 (serious) side effects occurred in 40% of patients, there were no Grade 4 or 5 treatment-related side effects, and no one stopped treatment because of side effects. One in five patients needed a dose reduction.

Why did the higher dose fail?

At the next dose up, 2 of 4 patients had dose-limiting toxicities. Early-phase trials exist precisely to find that line — the highest dose patients can take safely — and this one found that the lower dose was sweeter: strong responses with a manageable safety profile. The Phase 3 trial will use the lower dose.

My loved one has pancreatic cancer without an MTAP deletion. Is there still hope in this direction?

Yes, cautiously. The same trial's second pairing and the wider field of RAS inhibitors are aimed at broader groups, and researchers — including Tango — are studying PRMT5 combinations in tumors without MTAP deletion as well. The broader lesson of this trial is bigger than one subgroup: matching pancreatic cancer drugs to tumor genetics works, and every patient's tumor testing adds a map for what to try next.

How can I find out if a tumor is MTAP-deleted?

Ask the oncology team whether comprehensive genomic profiling (also called biomarker or molecular testing) has been done on the tumor tissue or a blood-based test. MTAP deletion and RAS/KRAS mutations are included on many standard panels. If testing was never done, ask whether it can still be performed on the original biopsy sample.

Sources

1. Tango Therapeutics — "Tango Presents Promising Results From Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy." Globe Newswire, October 23, 2026.
2. ClinicalTrials.gov — "A Study of Vopimetostat (TNG462) in Combination With a RAS(ON) Inhibitor in Patients With MTAP-deleted and RAS-mutant Solid Tumors." U.S. National Library of Medicine, study NCT06922591.

---

For more information on how HuMOLYTE can support your gut health during chemotherapy, visit our product page or consult your health care provider.

This blog was reviewed by Dr. Sourabh Kharait.

This blog post is for educational purposes only and is not intended as medical advice. Always consult with your healthcare provider before making changes to your treatment plan, hydration strategies, or diet. The information provided is based on general insights and may not apply to individual circumstances.

---